| Document |
Document Title |
|
WO/2022/229684A1 |
A process for preparing a chlorpheniramine maleate, comprising addition of a predetermined amount of an isopropyl alcohol and a maleic acid to obtain a mixture, heating the isopropyl alcohol and the maleic acid mixture at a predetermined...
|
|
WO/2022/232838A1 |
The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), ...
|
|
WO/2022/226668A1 |
The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable ...
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/228387A1 |
Provided are certain PARP inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2022/228556A1 |
Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. It also provides pharmaceu...
|
|
WO/2022/231410A1 |
The invention relates to new radiopharmaceuticals that inhibit fibroblast activation protein (iFAP), which are based on the molecule ((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl)pyrrolidin-2-yl)bo
ronic acid (HYNIC-iFAP), wherein the nitrog...
|
|
WO/2022/228576A1 |
A protein regulator-targeted compound and an application thereof. The compound is a compound represented by formula Ia, Ib or Ic. The compound has a good inhibition effect and protein degradation effect on a KRAS_G12D mutant.
|
|
WO/2022/226665A1 |
The present application relates to halo-substituted aza-heteroaryl compounds of Formula (I): (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically accep...
|
|
WO/2022/228535A1 |
Disclosed in the present invention is a preparation method for nicotine and an intermediate thereof, and particularly disclosed is a preparation method for 4-amino-1-pyridin-3-yl-butan-1-one, the method comprising the following steps: su...
|
|
WO/2022/232088A1 |
Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tau...
|
|
WO/2022/228496A1 |
Provided are compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as well as uses and methods for treating a disease mediated by C...
|
|
WO/2022/232632A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/229055A1 |
The present invention relates to substituted pyridazinones of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their use as h...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/229405A1 |
The present invention relates to new pyridine-sulfonamide derivatives of formula (I') as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the pr...
|
|
WO/2022/222964A1 |
A compound of formula (I) and a use thereof in medicine. The compound can be used to treat tumor.
|
|
WO/2022/223033A1 |
An SOS1 degrading agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound represented by formula I: S-L-E(I), wherein L is a linker chain, which connects S and E by means of covalent bond...
|
|
WO/2022/223554A1 |
The present invention relates to new 1H-pyrazole derivatives of formula (I) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for ...
|
|
WO/2022/223376A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2022/225238A1 |
The present invention relates to a heteroaryl derivative compound and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, and thus can be effectively used as a t...
|
|
WO/2022/222965A1 |
Provided are a compound of formula (I) of the present application and the use thereof in medicine, and the compound can be used to treat tumors.
|
|
WO/2022/224195A1 |
The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones,...
|
|
WO/2022/222913A1 |
The present invention provides a preparation method for L-nicotine. According to the method, L-nicotine having an optical purity of up to 99.7% can be obtained, and the total synthesis yield reaches 60-70%. In the whole preparation proce...
|
|
WO/2022/224223A1 |
Provided herein are compounds of formula (I) and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are cyclic dione compounds which are inhibitors of SARS-CoV-2 main protease (...
|
|
WO/2022/223661A1 |
Disclosed are TRPM8 modulators of formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/222966A1 |
A selective PARP1 inhibitor and an application thereof (I).
|
|
WO/2022/223022A1 |
Provided are a compound represented by general formula (I), or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, and a preparation method t...
|
|
WO/2022/224269A1 |
The present disclosure relates to co-crystals, salts and crystalline forms of Niraparib of Formula (I). More particularly, the present invention relates to novel polymorphic forms and synergistic pharmaceutical co-crystals comprising Nir...
|
|
WO/2022/224166A1 |
The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammato...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/225941A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/223025A1 |
A heterocyclic derivative inhibitor and a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutic...
|
|
WO/2022/226133A1 |
The instant disclosure describes compounds having IL-6 modulating activity, pharmaceutical compositions and kits thereof, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.
|
|
WO/2022/226172A1 |
The present disclosure relates to compounds which increase y-oscillations in the brain. The disclosure further relates to methods of treating neurodegenerative diseases or disorders with the compounds disclosed herein.
|
|
WO/2022/222914A1 |
The present invention provides a preparation method for L-nicotine, the method can obtain L-nicotine having an optical purity of more than 99.9%, which is much higher than that of similar products in the current market. The total yield o...
|
|
WO/2022/222921A1 |
Provided are a PARP inhibitor containing a piperazine structure, a preparation method therefor and the pharmaceutical use thereof. Specifically, provided are compounds represented by general formulas (1), (2), (3), (4) and (5) and/or a p...
|
|
WO/2022/224975A1 |
Provided is a compound represented by formula (I) [in formula (I): R1 represents a substituted or unsubstituted C1-6 alkylsulfonyl group; R2 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl...
|
|
WO/2022/222995A1 |
Provided is a picolinamide compound, and specifically disclosed is a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/220599A1 |
The present invention relates to a crystal form of a sphingosine-1-phosphate receptor agonist and, more specifically, to a crystal form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylmethyl]-pi...
|
|
WO/2022/219407A1 |
Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of Formula (I), wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered het...
|
|
WO/2022/218289A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/219541A1 |
Provided herein are uses of the compounds for the treatment of various indications, including prostate cancer and Kennedy's disease.
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/220625A1 |
The present invention relates to protein degrader conjugates and a use thereof. Particularly, the present invention relates to antigen-specific binding moiety-protein degrader conjugates, and a use of the antigen-specific binding moiety-...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/218296A1 |
The disclosure provides substituted fused bicyclic compounds as PARP inhibitors and the use thereof. This disclosure provides compounds represented by Formula I as below, wherein A1, A2, A3, R1, L, Cy and n are defined herein. The compou...
|
|
WO/2022/221165A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein W, R1, R2, R3, Q1 and Q2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of ...
|
|
WO/2022/220597A1 |
The present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist and, more particularly, to a crystalline form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylme...
|
|
WO/2022/220598A1 |
The present invention relates to a crystal form of a sphingosine-1-phosphate receptor agonist and, more specifically, to 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole-5-ylmethoxy)
-3,4-dihydro-naphthalene-2-ylmethyl]-piperidine-4-carbo...
|
